verified SJR 0,657 · Q2 • database Scopus / SJR & Web of Science indexed

United States · Lippincott Williams and Wilk...

workspace_premium Q2 — Oncology lock Subscription

Melanoma Research

Melanoma Research is a journal indexed in SJR in Oncology and Cancer Research with an H index of 82. It has an SJR impact factor of 0,657 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,657.

Melanoma Research focuses its scope in these topics and keywords: metastatic, melanoma, patients, survival, treated, patient, cutaneous, melanomasuccess, computed, biclonal, ...

ISSN: 0960-8931

Publisher: Lippincott Williams and Wilkins

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,657 Q2

H-index 82

Acceptance rate pie_chart

27% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,657

H-index

Docs (year)

Docs 3y

227

Total refs

2703

Cites 3y

381

Citable 3y

208

Cites/Doc 2y

1.69

Ref/Doc

34.65

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

CO02. Feasibility and effectiveness of a melanoma targeted screening strategy

Value of dopachrome tautomerase detection in the assessment of melanocytic tumors

CO16. The Mitogen Activated Protein Kinase pathway regulates the expression of p18INK4c and p21Waf1/Cip1 cyclin-dependent kinase inhibitors through the activating protein-1 transcription factor

CO15. The DEPIMELA study

CO13. Sinonasal mucosal melanomas. About the impact of initial localization and therapeutic modalities on survival

CO12. Chemoablation of metastatic melanoma with intralesional PV-10

CO11. 131I targeted radionuclide therapy by melanin linked molecules for melanoma treatment

CO10. Importance of duration of high-dose interferon-alfa in the adjuvant therapy of melanoma

CO09. Determinants of melanoma risk in a large case-control study

CO08. Prognostic value of S-100 protein concentration in the follow up of melanoma

CO06. Detection rate of sentinel node mapping using combined labeling technique in patients with cutaneous melanoma

CO04. Sun awareness among secondary school students from central Italy

SHOW MORE ARTICLES

CO03. Behavioral determinants of successful early melanoma detection

A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases

Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome

CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families

BRAF mutation screening in melanoma

Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression

Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines

Anti-programmed cell death-1 therapy-associated bullous disorders

Anti-??Gal-dependent complement-mediated cytotoxicity in metastatic melanoma

Animal-type malignant melanoma associated with nevus of Ota in the orbit of a Japanese woman

Akt and PI3K-dependent but CREB-independent upregulation of MCAM by endothelin-3 in human melanocytes

FAQs

Melanoma Research has an SJR of 0,657 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Melanoma Research is 27%.

Melanoma Research

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Melanoma Research?

What is the APC / publication cost?

What is the acceptance rate?